UiPath, Inc. (PATH) has announced that Director, 10% Owner, CEO, and Chairman Dines Daniel has sold 45,000 shares at a price of $12.06 per share on July 30, 2025.
UiPath, Inc. (NYSE:PATH) announced on July 30, 2025, that Director, 10% Owner, CEO, and Chairman Daniel Dines sold 45,000 shares of the company's stock at an average price of $12.06 per share. The total transaction value was $547,200.00. Following the sale, Dines owned 4,698,376 shares, valued at approximately $57,132,252.16. This sale represents a 0.95% decrease in his position [1].
Dines has been actively selling UiPath shares since July 2025. According to MarketBeat, he sold 45,000 shares on July 28, 2025, at an average price of $12.16, totaling $547,200.00. The stock's price on July 28, 2025, was $12.14, up $0.06 from the previous day. The stock's 50-day moving average is $12.67, and its 200-day moving average is $12.41 [1].
UiPath, Inc. provides an end-to-end automation platform, primarily focusing on robotic process automation (RPA) solutions. The company has seen a significant rally since its April lows, with revenue growth and profitability improvements. UiPath's full-year revenue outlook for FY25 is $1.549-$1.554 billion, representing an 8-9% year-over-year (y/y) growth [2].
The stock's market capitalization is $6.49 billion, with a price-to-earnings (P/E) ratio of -100.87 and a price-to-earnings-growth (PEG) ratio of 16.00. The stock's twelve-month low is $9.38, and its twelve-month high is $15.93. UiPath's enterprise value (EV) is $4.87 billion, with a free cash flow (FCF) margin of 19.7% for FY26 [2].
Institutional investors have been active in UiPath's stock. Versant Capital Management Inc., AdvisorNet Financial Inc., CX Institutional, GAMMA Investing LLC, and IFP Advisors Inc. have significantly increased their holdings in UiPath. As of July 2025, 62.50% of UiPath's stock is owned by institutional investors and hedge funds [1].
Wall Street analysts have mixed views on UiPath. Truist Financial and Scotiabank have raised their price targets to $13.00, while Canaccord Genuity Group has set a $16.00 price target. Mizuho has lowered its price target to $11.00. Barclays has maintained an "equal weight" rating. Two analysts have issued a sell rating, twelve have assigned a hold rating, two have assigned a buy rating, and one has issued a strong buy rating [1].
References:
[1] https://www.marketbeat.com/instant-alerts/daniel-dines-sells-45000-shares-of-uipath-inc-nysepath-stock-2025-07-28/
[2] https://seekingalpha.com/article/4805865-uipath-agentic-ai-strategy-taking-off-with-fcf-growing
Comments

No comments yet